ALFUZOSIN DIN 02414759
Health Canada record
| Active ingredient(s) | ALFUZOSIN HYDROCHLORIDE 10 MG |
|---|---|
| Dosage form | Tablet (Extended-Release) |
| Route | Oral |
| Schedule | PRESCRIPTION |
| Class | Human |
| ATC | G04CA01 ALFUZOSIN |
| Original market date | 21-Nov-2013 |
| Current status date | 30-Nov-2018 |
| Source | Health Canada DPD |
Establishment licence of the holder
Pro Doc Limitée — licence 100182, currently licensed, last inspection rating C (2025-08-11).
No Canadian shortage report is currently matched to this DIN.
Other Canadian products containing ALFUZOSIN HYDROCHLORIDE
| DIN | Product | Company | Form | Strength | Status |
|---|---|---|---|---|---|
| 02447576 | ALFUZOSIN | SIVEM PHARMACEUTICALS ULC | Tablet (Extended-Release) | ALFUZOSIN HYDROCHLORIDE 10 MG | Marketed |
| 02519844 | ALFUZOSIN | SANIS HEALTH INC | Tablet (Extended-Release) | ALFUZOSIN HYDROCHLORIDE 10 MG | Marketed |
| 02315866 | APO-ALFUZOSIN | APOTEX INC | Tablet (Extended-Release) | ALFUZOSIN HYDROCHLORIDE 10 MG | Marketed |
| 02443201 | AURO-ALFUZOSIN | AURO PHARMA INC | Tablet (Extended-Release) | ALFUZOSIN HYDROCHLORIDE 10 MG | Marketed |
| 02304678 | SANDOZ ALFUZOSIN | SANDOZ CANADA INCORPORATED | Tablet (Extended-Release) | ALFUZOSIN HYDROCHLORIDE 10 MG | Marketed |
| 02245565 | XATRAL | SANOFI-AVENTIS CANADA INC | Tablet (Extended-Release) | ALFUZOSIN HYDROCHLORIDE 10 MG | Marketed |
| 02314282 | TEVA-ALFUZOSIN PR | TEVA CANADA LIMITED | Tablet (Extended-Release) | ALFUZOSIN HYDROCHLORIDE 10 MG | Cancelled Post Market |
Notices of Compliance
| NOC | Date | Submission | Reason |
|---|---|---|---|
| 14894 | 2013-11-08 | New Drug Submission (NDS) | LICENSING AGREEMENT BETWEEN TWO COMPANIES |
International API supply for ALFUZOSIN HYDROCHLORIDE
5 valid EDQM Certificates of Suitability from 5 holders. 9 active FDA Drug Master Files.
Request a quote for ALFUZOSIN